Eli Lilly and CompanyLLY expanded its existing immuno oncology partnership with China based biotech company, Innovent Biologics, Inc. and acquired worldwide rights to an intranasal glucagon candidate. Expands Immuno Oncology Deal with Innovent Eli Lilly and Innovent will collaborate
Eli Lilly Inks Deals, Immuno-Oncology & Diabetes in Focus
